A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

Net Margin: Vertex Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 37.71%, the company demonstrates strong profitability and effective cost management.

(You can read the full research report on Vertex Pharmaceuticals here >>>) Shares ... Gross margins rose to 38.8%, driven by cost reductions and a favorable product mix, particularly high-margin ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

These granules, available in 25 mg, 50 mg, and 75 mg per unit dose packets, are a generic equivalent of Kalydeco Oral ...

That can create a “potential snowball effect” of bias that further amplifies human behavior, one researcher said in a press release, partly because the authors said people seem to believe AI is more ...

Vertex Pharmaceuticals Inc. notched two FDA victories ... That’s higher than the twice-daily Trikafta wholesale acquisition cost of $346,048 per year. Minter said William Blair “conservatively ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance in ...

T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.

As Vertex Pharmaceuticals reels from a painful trial ... which is 7% higher than Trikafta’s annual wholesale acquisition cost of $346,048, according to a securities filing.